Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Abattis Bioceuticals Corp. ATTBF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score
27/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Abattis Bioceuticals Corp. (ATTBF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 26/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $356,876, +4163.2%/yr average growth. Net income is $3M (loss), growing at -350.7%/yr. Net profit margin is -852.4% (negative). Gross margin is 67.6% (-9.8 pp trend).

Balance sheet: total debt is $2M against $11M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 0.73 (tight liquidity). Debt-to-assets is 8.1%. Total assets: $19M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 35/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

ATTBF SharesGrow Score Overview

34/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATTBF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
ATTBF: +4163.2%/yr revenue is, -350.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet ATTBF: Debt-to-Equity (D/E) ratio 0.14 (conservative), Current ratio is 0.73 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
ATTBF: Gross margin is 67.6% (-9.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ATTBF: Net profit margin is -852.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.000001-0.0001
Volume2.48K
Avg Volume (30D)25.37K
Market Cap$14.33K
Beta (1Y)-46.51
Share Statistics
EPS (TTM)-0.01
Shares Outstanding$470.49M
IPO Date2014-05-29
CEOFrancesco Paolini
Financial Highlights & Ratios
Revenue (TTM)$356.88K
Gross Profit$241.34K
EBITDA$-3.85M
Net Income$-3.04M
Operating Income$-3.96M
Total Cash$2.4M
Total Debt$1.57M
Net Debt$-449.84K
Total Assets$19.26M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.04
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA00258G1037

Price Chart

Track all markets on TradingView
ATTBF
Abattis Bioceuticals Corp. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.00 52WK RANGE 0.00

People Also View

APNHF
APNHF
Aspen Pharmacare Holdings Limited
$8.69
+0.00%
 ATHJF
ATHJF
Antisense Therapeutics Limited
$0.01
-76.00%
 CRRTF
CRRTF
Crescita Therapeutics Inc.
$0.54
+0.00%
 ABTI
ABTI
Alterola Biotech, Inc.
$0.01
+0.00%
 BCBCF
BCBCF
The BC Bud Corporation
$0.04
-3.31%
 ANTCF
ANTCF
Aion Therapeutic Inc.
$0.00
+0.00%
 ACNNF
ACNNF
AusCann Group Holdings Ltd
$0.00
-15.56%
 AXRX
AXRX
Amexdrug Corporation
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message